Brookline Capital Management Weighs in on Kymera Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:KYMR)

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Brookline Capital Management increased their Q1 2024 earnings per share estimates for Kymera Therapeutics in a research report issued on Monday, April 8th. Brookline Capital Management analyst L. Cann now expects that the company will post earnings per share of ($0.57) for the quarter, up from their prior estimate of ($0.67). The consensus estimate for Kymera Therapeutics' current full-year earnings is ($3.16) per share. Brookline Capital Management also issued estimates for Kymera Therapeutics' Q2 2024 earnings at ($0.41) EPS, Q3 2024 earnings at ($0.73) EPS, Q4 2024 earnings at ($0.17) EPS and FY2024 earnings at ($1.89) EPS.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings results on Thursday, February 22nd. The company reported ($0.25) EPS for the quarter, beating analysts' consensus estimates of ($0.44) by $0.19. The company had revenue of $47.90 million for the quarter, compared to analyst estimates of $41.94 million. Kymera Therapeutics had a negative return on equity of 34.83% and a negative net margin of 187.00%. The company's quarterly revenue was up 197.5% compared to the same quarter last year. During the same period last year, the company earned ($0.60) earnings per share.

A number of other research analysts have also commented on the stock. JPMorgan Chase & Co. raised their price objective on shares of Kymera Therapeutics from $34.00 to $47.00 and gave the company an "overweight" rating in a research note on Friday, February 23rd. Wells Fargo & Company downgraded Kymera Therapeutics from an "overweight" rating to an "equal weight" rating and set a $26.00 price objective on the stock. in a research note on Tuesday, December 19th. Wolfe Research started coverage on Kymera Therapeutics in a research note on Thursday, February 15th. They set a "peer perform" rating for the company. Truist Financial lifted their target price on Kymera Therapeutics from $41.00 to $54.00 and gave the stock a "buy" rating in a report on Friday, March 1st. Finally, Bank of America downgraded shares of Kymera Therapeutics from a "buy" rating to a "neutral" rating and cut their price target for the company from $45.00 to $30.00 in a report on Wednesday, January 3rd. Six investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $39.89.

Kymera Therapeutics Stock Up 5.3 %

Kymera Therapeutics stock traded up $1.88 during trading hours on Thursday, hitting $37.21. 469,853 shares of the company traded hands, compared to its average volume of 762,384. Kymera Therapeutics has a 1-year low of $9.60 and a 1-year high of $45.31. The firm has a market cap of $2.27 billion, a P/E ratio of -14.77 and a beta of 2.27. The firm's 50-day simple moving average is $39.15 and its two-hundred day simple moving average is $27.04.

Institutional Investors Weigh In On Kymera Therapeutics

A number of institutional investors have recently bought and sold shares of KYMR. Price T Rowe Associates Inc. MD boosted its stake in shares of Kymera Therapeutics by 5.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,335,712 shares of the company's stock valued at $135,848,000 after buying an additional 278,287 shares during the period. BVF Inc. IL raised its holdings in shares of Kymera Therapeutics by 8.9% during the fourth quarter. BVF Inc. IL now owns 5,161,801 shares of the company's stock worth $131,419,000 after acquiring an additional 422,797 shares in the last quarter. Vanguard Group Inc. boosted its position in Kymera Therapeutics by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 3,997,564 shares of the company's stock valued at $101,778,000 after purchasing an additional 72,351 shares during the last quarter. State Street Corp grew its stake in Kymera Therapeutics by 67.8% in the second quarter. State Street Corp now owns 3,514,438 shares of the company's stock valued at $69,199,000 after purchasing an additional 1,419,877 shares in the last quarter. Finally, BlackRock Inc. increased its position in Kymera Therapeutics by 0.6% in the 1st quarter. BlackRock Inc. now owns 3,419,084 shares of the company's stock worth $144,698,000 after purchasing an additional 21,544 shares during the last quarter.

Insider Activity at Kymera Therapeutics

In other news, Director Bruce Booth sold 71,764 shares of Kymera Therapeutics stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $40.46, for a total value of $2,903,571.44. Following the transaction, the director now directly owns 806,697 shares of the company's stock, valued at $32,638,960.62. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, major shareholder Venture Fund X. L.P. Atlas sold 115,090 shares of the firm's stock in a transaction on Wednesday, March 13th. The stock was sold at an average price of $42.23, for a total value of $4,860,250.70. Following the completion of the sale, the insider now owns 4,676,075 shares of the company's stock, valued at $197,470,647.25. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Bruce Booth sold 71,764 shares of the company's stock in a transaction on Friday, March 15th. The shares were sold at an average price of $40.46, for a total value of $2,903,571.44. Following the transaction, the director now directly owns 806,697 shares in the company, valued at $32,638,960.62. The disclosure for this sale can be found here. Insiders sold 484,051 shares of company stock worth $19,924,711 in the last quarter. 16.67% of the stock is owned by company insiders.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.